Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

X
Trial Profile

A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Canagliflozin (Primary)
  • Indications Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction; Renal failure; Stroke; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms CREDENCE
  • Sponsors Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 01 Apr 2024 Results assessing the association of angiopoietin 2 and VEGF-A with cardiorenal outcomes and investigated the effect of canagliflozin on angiopoietin 2 and VEGF-A concentration, published in the Clinical Journal of The American Society of Nephrology: CJASN
    • 04 Jan 2024 Results of pooled analysis from CANVAS Program and CREDENCE assessing Treatment effect of canagliflozin for patients on therapy for heart failure, published in the International Journal of Cardiology
    • 30 Nov 2023 Results of pooled analysis assessing effects of canagliflozin on clinical outcomes and intermediate markers of subgroups according to population-specific BMI , from the NCT01032629, NCT01989754 and NCT02065791 studies published in the Diabetes, Obesity and Metabolism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top